




RealRate

PHARMACEUTICAL 2024

Ensysce Biosciences Inc
Rank 290 of 309



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Ensysce Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ensysce Biosciences Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 6.1% points. The greatest weakness of Ensysce Biosciences Inc is the variable Assets, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is 40%, being 173% points below the market average of 213%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	2,289	Assets	2,708
Cost of Goods Sold	0	Liabilities	3,359
Intangible Assets	0	Expenses	12,949
Liabilities, Current	3,333	Revenues	2,231
Liabilities, Non-Current	26	Stockholders Equity	-651
Other Assets	419	Net Income	-10,626
Other Compr. Net Income	0	Comprehensive Net Income	-10,626
Other Expenses	0	BaseVar	10,669
Other Liabilities	0	ECR before LimitedLiability	-397%
Other Net Income	92	Economic Capital Ratio	40%
Other Revenues	2,231		
Property and Equipment	0		
Research and Development	7,587		
Selling, General and Administrative Expense	5,361		